Regeneron Pharmaceuticals

Regeneron Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
1988-01-01
Employees
13.4K
Market Cap
$132.4B
Website
http://www.regeneron.com
Introduction

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...

Clinical Trials
Related News

Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

Phase 1
Terminated
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: REGN1193
Drug: Placebo
First Posted Date
2014-11-06
Last Posted Date
2016-05-12
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
72
Registration Number
NCT02284425

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

First Posted Date
2014-10-29
Last Posted Date
2020-06-02
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
708
Registration Number
NCT02277769

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

First Posted Date
2014-10-29
Last Posted Date
2017-11-21
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
671
Registration Number
NCT02277743

Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

First Posted Date
2014-10-16
Last Posted Date
2019-12-09
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
9
Registration Number
NCT02265952

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

First Posted Date
2014-10-09
Last Posted Date
2017-10-17
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
740
Registration Number
NCT02260986

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
Drug: Dupilumab
First Posted Date
2014-08-07
Last Posted Date
2020-05-07
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
194
Registration Number
NCT02210780

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Phase 1
Completed
Conditions
Allergy
Interventions
Drug: REGN1908-1909
Drug: placebo
First Posted Date
2014-05-01
Last Posted Date
2020-12-16
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
74
Registration Number
NCT02127801

Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: REGN2222(SAR438584)
Drug: placebo
First Posted Date
2014-04-23
Last Posted Date
2015-03-11
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
132
Registration Number
NCT02121080

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Phase 1
Completed
Conditions
Metabolic Disorders
Interventions
Drug: REGN1500
Drug: placebo
First Posted Date
2014-04-08
Last Posted Date
2015-09-30
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
55
Registration Number
NCT02107872

Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Sarilumab
Drug: Tocilizumab
First Posted Date
2014-03-27
Last Posted Date
2015-05-05
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
105
Registration Number
NCT02097524
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy